Clinical Trial Update: Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Late-onset Neonatal Sepsis

View source ↗

Summary

A clinical trial update evaluating soluble urokinase plasminogen activator receptor (suPAR) for late-onset neonatal sepsis, sponsored by Ankara University; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Sepsis

Snippet

Sponsor: Ankara University | Conditions: Neonatal Sepsis | Status: UNKNOWN